[go: up one dir, main page]

LU92681I2 - Nintédanib, ses tautomères et ses sels, en particulier Nintédanib et ses sels pharmaceutiquement acceptables, en particulier Nintédanib Esilate - Google Patents

Nintédanib, ses tautomères et ses sels, en particulier Nintédanib et ses sels pharmaceutiquement acceptables, en particulier Nintédanib Esilate

Info

Publication number
LU92681I2
LU92681I2 LU92681C LU92681C LU92681I2 LU 92681 I2 LU92681 I2 LU 92681I2 LU 92681 C LU92681 C LU 92681C LU 92681 C LU92681 C LU 92681C LU 92681 I2 LU92681 I2 LU 92681I2
Authority
LU
Luxembourg
Prior art keywords
nintédanib
salts
esilate
tautomers
pharmaceutically acceptable
Prior art date
Application number
LU92681C
Other languages
English (en)
Other versions
LU92681I9 (fr
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26006858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92681(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19949208A external-priority patent/DE19949208A1/de
Priority claimed from DE2000142696 external-priority patent/DE10042696A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of LU92681I2 publication Critical patent/LU92681I2/fr
Publication of LU92681I9 publication Critical patent/LU92681I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LU92681C 1999-10-13 2015-03-16 Nintédanib, ses tautomères et ses sels, en particulier Nintédanib et ses sels pharmaceutiquement acceptables, en particulier Nintédanib Esilate LU92681I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19949208A DE19949208A1 (de) 1999-10-13 1999-10-13 In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE2000142696 DE10042696A1 (de) 2000-08-31 2000-08-31 In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
PCT/EP2000/009867 WO2001027081A1 (fr) 1999-10-13 2000-10-09 Indolinones substituees en position 6, leur preparation et leur utilisation en tant que medicaments

Publications (2)

Publication Number Publication Date
LU92681I2 true LU92681I2 (fr) 2015-05-18
LU92681I9 LU92681I9 (fr) 2019-01-03

Family

ID=26006858

Family Applications (1)

Application Number Title Priority Date Filing Date
LU92681C LU92681I2 (fr) 1999-10-13 2015-03-16 Nintédanib, ses tautomères et ses sels, en particulier Nintédanib et ses sels pharmaceutiquement acceptables, en particulier Nintédanib Esilate

Country Status (43)

Country Link
EP (2) EP1224170B9 (fr)
JP (2) JP4021664B2 (fr)
KR (2) KR100857734B1 (fr)
CN (1) CN100455568C (fr)
AR (1) AR026036A1 (fr)
AT (1) ATE439342T1 (fr)
AU (1) AU781939B2 (fr)
BE (1) BE2015C018I2 (fr)
BG (1) BG65983B1 (fr)
BR (1) BRPI0014735B8 (fr)
CA (1) CA2387013C (fr)
CO (1) CO5261488A1 (fr)
CY (2) CY1110067T1 (fr)
CZ (1) CZ301073B6 (fr)
DE (1) DE50015711D1 (fr)
DK (1) DK1224170T5 (fr)
EA (1) EA006080B1 (fr)
EE (1) EE05427B1 (fr)
EG (1) EG25931A (fr)
ES (1) ES2331459T3 (fr)
FR (1) FR15C0024I2 (fr)
HK (1) HK1052505B (fr)
HR (1) HRP20020306B1 (fr)
HU (2) HU230416B1 (fr)
IL (2) IL148756A0 (fr)
LT (1) LTC1224170I2 (fr)
LU (1) LU92681I2 (fr)
ME (1) MEP45408A (fr)
MX (1) MXPA02002799A (fr)
MY (1) MY127956A (fr)
NL (1) NL300725I2 (fr)
NO (3) NO322746B1 (fr)
NZ (1) NZ518489A (fr)
PE (1) PE20010671A1 (fr)
PL (1) PL207445B1 (fr)
PT (1) PT1224170E (fr)
RS (1) RS51013B (fr)
SA (1) SA01210704B1 (fr)
SI (1) SI1224170T1 (fr)
SK (1) SK287312B6 (fr)
TW (1) TWI268922B (fr)
UA (1) UA75054C2 (fr)
WO (1) WO2001027081A1 (fr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE60134679D1 (de) 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
US6638965B2 (en) 2000-11-01 2003-10-28 Boehringer Ingelheim Pharma Kg Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
DE10117204A1 (de) 2001-04-06 2002-10-10 Boehringer Ingelheim Pharma In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
US7727731B2 (en) 2001-06-29 2010-06-01 Ab Science Potent, selective and non toxic c-kit inhibitors
ATE343415T1 (de) 2001-06-29 2006-11-15 Ab Science Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
JP2004537536A (ja) 2001-06-29 2004-12-16 アブ サイエンス アレルギー疾患を治療するためのチロシンキナーゼ阻害剤の使用方法
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
US20050176687A1 (en) * 2001-06-29 2005-08-11 Alain Moussy Use of tyrosine kinase inhibitors for treating autoimmune diseases
DK1401415T3 (da) 2001-06-29 2006-10-16 Ab Science Anvendelse af N-phenyl-2-pyrimidinamin-derivater til behandling af inflammatoriske sygdomme
US20030225152A1 (en) * 2001-09-27 2003-12-04 Andrews Steven W. 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
ES2247411T3 (es) 2001-12-27 2006-03-01 Theravance, Inc. Derivados de indolinona utiles como inhibidores de la proteina kinasa.
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
ITBO20020198A1 (it) * 2002-04-12 2003-10-13 Univ Bologna Derivati 2 , 5 bis diammino 1 , 4 benzochenionici utili per il trattamento della malattia di alzheimer , metodo per la loro preparazione ed
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10233500A1 (de) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
US7148249B2 (en) * 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
JP4879492B2 (ja) * 2002-11-27 2012-02-22 アラーガン、インコーポレイテッド 疾患の治療のためのキナーゼ阻害剤
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP2364699A1 (fr) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Utilisation conjointe d'un composé à base de sulfonamide avec un inhibiteur de l'angiogénèse
ES2322175T3 (es) 2004-09-17 2009-06-17 EISAI R&D MANAGEMENT CO., LTD. Composicion medicinal con estabilidad mejorada y gelificacion reducida.
PE20060777A1 (es) * 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US9006240B2 (en) 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
WO2007057397A1 (fr) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Traitement du cancer
CA2652442C (fr) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Agent antitumoral destine au cancer de la thyroide
EP1870400A1 (fr) * 2006-06-08 2007-12-26 Boehringer Ingelheim Pharma GmbH & Co. KG Sels et sels cristallines d'un produit 2-indolinone
EP2065372B1 (fr) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
JP5319306B2 (ja) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
EP2167465A1 (fr) * 2007-06-12 2010-03-31 Boehringer Ingelheim International GmbH Dérivés d'indolinone et leur utilisation dans le traitement d'états pathologiques tels que le cancer
AU2008265104B2 (en) 2007-06-21 2013-09-12 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
PE20091445A1 (es) * 2007-12-03 2009-10-19 Boehringer Ingelheim Int Derivados de indolinona y procedimiento para su fabricacion
RU2525114C2 (ru) * 2007-12-03 2014-08-10 Бёрингер Ингельхайм Интернациональ Гмбх Способ получения производного индолинона
DK2985025T3 (en) 2008-06-06 2018-03-19 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION
NZ590560A (en) 2008-07-29 2012-12-21 Boehringer Ingelheim Int Indolinone Inhibitors of cell cycle kinases
US20120157472A1 (en) 2009-01-14 2012-06-21 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
WO2010108503A1 (fr) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion de l'intégration neuronale dans des greffons de cellules souches neurales
EP2429520A1 (fr) 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH Nouvelle polytherapie destinee a traiter les maladies oncologiques et fibrotiques
AU2010285740C1 (en) 2009-08-19 2016-03-17 Eisai R&D Management Co., Ltd. Quinoline derivative-containing pharmaceutical composition
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
WO2012068441A2 (fr) 2010-11-19 2012-05-24 Ratiopharm Gmbh Sels d'intedanib et leurs formes à l'état solide
JP6021805B2 (ja) 2011-04-18 2016-11-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
EP3444363B1 (fr) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
WO2013059740A1 (fr) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Nouvelles molécules de fusion alk et ntrk1 et leurs utilisations
DK2807160T3 (da) 2012-01-26 2019-10-14 Angion Biomedica Corp Antifibrotiske forbindelser og anvendelser deraf
ES2949394T3 (es) 2012-11-05 2023-09-28 Found Medicine Inc Moléculas de fusión novedosas y usos de las mismas
AU2013337277B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel NTRK1 fusion molecules and uses thereof
US9642851B2 (en) 2012-12-06 2017-05-09 Kbp Biosciences Co., Ltd. Indolinone derivative as tyrosine kinase inhibitor
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US20140350022A1 (en) 2013-05-10 2014-11-27 Boehringer Ingelheim International Gmbh Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN104003925B (zh) * 2013-06-05 2016-03-30 四川大学 吲哚酮化合物或其衍生物及其用途
WO2015009889A1 (fr) * 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Dérivés deutériés d'intédanib et leur utilisation pour le traitement de troubles prolifératifs
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP6659554B2 (ja) 2014-08-28 2020-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 高純度キノリン誘導体およびその製造方法
CN104262232B (zh) * 2014-09-09 2016-05-04 苏州明锐医药科技有限公司 尼泰达尼的制备方法
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
WO2016178064A1 (fr) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorphe d'éthanesulfonate de nintedanib, procédés et intermédiaires associés
CN104844499B (zh) * 2015-06-05 2017-03-08 北京康立生医药技术开发有限公司 一锅法制备尼达尼布的合成方法
CN114010787A (zh) 2015-06-06 2022-02-08 拨云生物医药科技(广州)有限公司 用于治疗翼状胬肉的组合物和方法
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
CN105126909B (zh) * 2015-07-13 2018-01-23 淮海工学院 固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用
CZ308695B6 (cs) 2015-07-29 2021-03-03 Zentiva, K.S. Způsob přípravy methyl (Z)-3[[4-[methyl[2-(4-methyl-1piperazinyl)acetyl]amino]fenyl]amino]fenylmethylen)-oxindol-6karboxylátu (intedanibu, nintedanibu)
CN106467500A (zh) * 2015-08-14 2017-03-01 廊坊百瑞化工有限公司 一种一锅煮法合成尼达尼布关键中间体的新方法
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
HUE062784T2 (hu) * 2015-12-24 2023-12-28 Respivert Ltd Indolinon vegyületek és alkalmazásuk fibrotikus betegségek kezelésében
CZ2016104A3 (cs) 2016-02-24 2017-09-06 Zentiva, K.S. Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy
BR112018068213A2 (pt) 2016-03-08 2019-01-29 Respivert Ltd derivados indólicos e seu uso como inibidores de proteína quinase
WO2017178428A1 (fr) 2016-04-13 2017-10-19 Boehringer Ingelheim International Gmbh Combinaison pharmaceutique de nintédanib, de trifluridine et de tipiracil pour le traitement du cancer colorectal
EP3246029A1 (fr) 2016-05-19 2017-11-22 Boehringer Ingelheim International Gmbh Combinaison pharmaceutique de nintedanib et de capécitabine dans le traitement du cancer colorectal
JP2019522638A (ja) 2016-05-27 2019-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ニンテダニブ及びピルフェニドンによる治療開始を判定するためのｅｃｍバイオマーカーの使用
WO2017207643A1 (fr) 2016-06-01 2017-12-07 Boehringer Ingelheim International Gmbh Utilisation de biomarqueurs de matrice extracellulaire pour déterminer le moment d'instauration d'un traitement sous nintédanib et pirfénidone
WO2017210130A1 (fr) 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions et procédés d'utilisation de nintedanib pour améliorer le taux de réussite de la chirurgie du glaucome
SG11201811661TA (en) 2016-07-29 2019-01-30 Oncternal Therapeutics Inc Uses of indolinone compounds
CN106748961A (zh) * 2016-11-30 2017-05-31 瑞阳制药有限公司 尼达尼布的杂质化合物、制备方法、应用及其检测方法
CN106748960A (zh) * 2016-11-30 2017-05-31 瑞阳制药有限公司 尼达尼布的潜在杂质化合物、制备方法、应用及其检测方法
US20200069679A1 (en) 2016-12-12 2020-03-05 Boehringer Ingelheim International Gmbh Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
JP2020512364A (ja) 2017-03-28 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 筋ジストロフィーの処置方法において使用するためのニンテダニブ
KR20200013644A (ko) 2017-05-16 2020-02-07 에자이 알앤드디 매니지먼트 가부시키가이샤 간세포 암종의 치료
FI3700529T3 (fi) 2017-10-23 2025-09-18 Boehringer Ingelheim Int Uusi aktiivisten aineiden yhdistelmä etenevien fibrotisoivien interstitiaalisten keuhkosairauksien (pf-ild) hoitoon
US11261158B2 (en) 2017-11-17 2022-03-01 Fermion Oy Synthesis of 2-indolinone derivatives
JP7061310B2 (ja) * 2018-04-05 2022-04-28 国立大学法人 大分大学 慢性脂肪性疾患の予防および治療用医薬
CN108358827A (zh) * 2018-05-07 2018-08-03 日照市普达医药科技有限公司 一种治疗牛皮癣的2-氧代-吲哚类衍生物及其制备方法
WO2019226864A1 (fr) 2018-05-25 2019-11-28 Scott Whitcup Composition pour le traitement de l'hyperémie oculaire et procédé de traitement de l'hyperémie oculaire au moyen de celle-ci
PH12021550742A1 (en) * 2018-10-05 2023-02-27 Ichnos Sciences S A Indolinone compounds for use as map4k1 inhibitors
US20230135671A1 (en) 2020-04-01 2023-05-04 Boehringer Ingelheim International Gmbh Use of biomarkers in the treatment of fibrotic conditions
CN111848490B (zh) * 2020-08-24 2021-09-24 江西国药有限责任公司 一种高纯度乙磺酸尼达尼布的制备方法
CN112574094B (zh) * 2020-12-14 2022-07-01 成都大学 吲哚酮衍生物及其制药用途
US20240238368A1 (en) 2021-01-25 2024-07-18 Nibec Co., Ltd. Peptide for preventing and treating fibrosis
EP4098246A1 (fr) 2021-05-31 2022-12-07 Lotus Pharmaceutical Co., Ltd. Formulation de nintedanib
CN115703758B (zh) * 2021-08-12 2024-03-26 中国医学科学院药物研究所 一类用作激酶抑制剂的化合物及其制备方法和用途
CN119630398A (zh) 2022-08-16 2025-03-14 勃林格殷格翰国际有限公司 眼内用尼达尼布的药物制剂
TWI857798B (zh) * 2023-09-28 2024-10-01 國立臺灣大學 用於治療及/或預防腫瘤或細胞增生及纖維化疾病之吲哚啉衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL96047C (fr) * 1956-06-08
EP0708646A1 (fr) * 1994-05-06 1996-05-01 Alcon Laboratories, Inc. Utilisation de derives tocopheryle de vitamine e dans des compositions ophtalmiques
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
DE69722858T2 (de) * 1996-01-17 2004-05-13 Taiho Pharmaceutical Co. Ltd. Intimale verdickungsinhibitoren
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE19815020A1 (de) * 1998-04-03 1999-10-07 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19816624A1 (de) * 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
DE19824922A1 (de) 1998-06-04 1999-12-09 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
HK1052505A1 (en) 2003-09-19
EP1224170B1 (fr) 2009-08-12
PE20010671A1 (es) 2001-06-28
CY2015009PI2 (el) 2016-12-14
PL355433A1 (pl) 2004-04-19
BE2015C018I2 (fr) 2019-10-23
HRP20020306A2 (en) 2003-10-31
NO2015009I2 (fr) 2015-03-18
DE50015711D1 (de) 2009-09-24
RS51013B (sr) 2010-10-31
BRPI0014735B1 (pt) 2012-07-10
NL300725I2 (nl) 2017-07-13
DK1224170T5 (en) 2018-01-22
BRPI0014735A (pt) 2002-07-16
ES2331459T3 (es) 2010-01-05
PL207445B1 (pl) 2010-12-31
CN100455568C (zh) 2009-01-28
NO20021719L (no) 2002-04-11
LU92681I9 (fr) 2019-01-03
HUS1600022I1 (hu) 2017-02-28
MXPA02002799A (es) 2003-02-27
SI1224170T1 (sl) 2009-12-31
EE05427B1 (et) 2011-06-15
CY2015009PI1 (el) 2016-12-14
KR100857734B1 (ko) 2008-09-10
CO5261488A1 (es) 2003-03-31
CZ301073B6 (cs) 2009-10-29
HUP0204587A2 (en) 2003-05-28
SK6462002A3 (en) 2002-08-06
MEP45408A (en) 2011-02-10
JP2003511441A (ja) 2003-03-25
IL148756A (en) 2007-10-31
KR20020038949A (ko) 2002-05-24
TWI268922B (en) 2006-12-21
AU1023301A (en) 2001-04-23
CN1391557A (zh) 2003-01-15
BG106587A (bg) 2003-01-31
NO2023033I1 (no) 2023-09-05
HU230416B1 (hu) 2016-05-30
NZ518489A (en) 2005-05-27
KR20070095996A (ko) 2007-10-01
SA01210704B1 (ar) 2006-12-05
BG65983B1 (bg) 2010-08-31
CA2387013A1 (fr) 2001-04-19
UA75054C2 (uk) 2006-03-15
SK287312B6 (sk) 2010-06-07
DK1224170T3 (da) 2009-12-07
EA006080B1 (ru) 2005-08-25
NO20021719D0 (no) 2002-04-11
HUP0204587A3 (en) 2004-07-28
FR15C0024I2 (fr) 2016-08-26
BRPI0014735B8 (pt) 2021-07-06
WO2001027081A1 (fr) 2001-04-19
HRP20020306B1 (en) 2010-09-30
EE200200197A (et) 2003-06-16
ATE439342T1 (de) 2009-08-15
EP1224170B9 (fr) 2017-11-22
IL148756A0 (en) 2002-09-12
JP2007302697A (ja) 2007-11-22
LTPA2015015I1 (lt) 2015-04-27
FR15C0024I1 (fr) 2015-04-17
HK1052505B (zh) 2009-06-26
EP1224170A1 (fr) 2002-07-24
LTC1224170I2 (lt) 2023-11-10
EA200200380A1 (ru) 2002-10-31
EG25931A (en) 2012-10-24
AR026036A1 (es) 2002-12-26
MY127956A (en) 2007-01-31
AU781939B2 (en) 2005-06-23
YU26602A (sh) 2004-11-25
CZ20021410A3 (cs) 2002-07-17
CY1110067T1 (el) 2015-01-14
JP4021664B2 (ja) 2007-12-12
KR100835546B1 (ko) 2008-06-09
CA2387013C (fr) 2009-12-29
NO322746B1 (no) 2006-12-04
NO2015009I1 (no) 2015-03-30
PT1224170E (pt) 2009-10-01
EP2157081A1 (fr) 2010-02-24

Similar Documents

Publication Publication Date Title
LU92681I2 (fr) Nintédanib, ses tautomères et ses sels, en particulier Nintédanib et ses sels pharmaceutiquement acceptables, en particulier Nintédanib Esilate
LU91501I2 (fr) Sugammadex et ses sels pharmaceutiquement acceptables-BRIDION
LU92182I2 (fr) Dapagliflozine et ses sels pharmaceutiquement acceptables
LU91785I2 (fr) Rapiscan - régadénoson et ses sels.
LU91363I2 (fr) Méthoxy polyéthylène glycol-époétine bêta et ses sels pharmaceutiquement acceptables (MIRCERA)
LU91650I2 (fr) Saxagliptine et sels pharmaceutiquement acceptables de celle-ci, y compris l'hydrochlorure de saxagliptine - Onglyza-saxagliptin
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
DE60139964D1 (de) Bakterielle Gyrase-Hemmer sowie deren Verwendung
LU91076I2 (fr) Tulathromycin et ses sels pharmaceutiquement acceptables (draxxin).
MXPA03005923A (es) Derivados de glupopiranosiloxipirazol y su uso en medicinas.
NO20015362L (no) Heterocyklisk substituerte benzimidazoler, deres fremstilling og anvendelse derav
NO2008001I1 (no) Vildagliptin og farmasoytisk akseptable salter derav
SI1326862T1 (sl) Kristalinični monohidrat tiotropijevega bromida, postopek za njegovo pripravo in njegova uporaba za pripravo zdravila
ZA200202479B (en) Heterocyclic sodium/proton exchange inhibitors and method.
NO20025154L (no) Imidazopyrimidinderivater og triazolpyrimidinderivater
MXPA03005713A (es) Derivados de tetrahidropiridina, su preparacion y su uso como inhibidores de proliferacion celular.
PL356427A1 (en) Indol-3-yl derivatives and their use as integrin inhibitors
LU91345I2 (fr) Rufinamide et ses sels pharmaceutiquement acceptables (inovelon)
DE60023642D1 (de) Walzwerk
ZA200207489B (en) Apomorphine derivatives and methods for their use.
AU5066900A (en) Benzimidazole derivatives and their use as methionyl t-rna synthetase inhibitors
NO20015897L (no) Indolylpiperidinderivater som antihistaminiske og antiallergiske midler
NO20024598D0 (no) Farmasöytisk aktive pyrrolidinderivater
NO20016419D0 (no) Melagatran i vesentlig krystallinsk form
AU2001276027A1 (en) Heteroaryl-beta-alanine derivatives as alpha 4 integrin inhibitors